Inclusion Criteria:

• Pathologically confirmed non-lymphoma liver metastases or
• New radiographic liver lesions consistent with metastases in patients with known pathologically confirmed non-lymphoma cancer
• 1-3 liver lesions measurable on CT/MRI or PET/CT performed within 6 weeks prior to study entry
• Liver metastases measuring \<5cm
• Life expectancy \>6 months
• Disease outside the liver is allowed
• Age ≥ 18
• ECOG Performance Scale = 0-1
• Adequate bone marrow function, defined as follows:
• * Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 based upon CBC/differential obtained within 4 weeks prior to registration on study
• * Platelets ≥ 60,000 cell/mm3 based upon CBC/differential obtained within 4 weeks prior to registration on study
• * Hemoglobin ≥ 8.0 g/dl based upon CBC/differential obtained within 4 weeks prior to registration on study (Note: the use of transfusion or other intervention to achieve Hgb ≥ 8.0 is acceptable.)
• Adequate kidney function (serum creatinine \<2mg/dL) based on chemistry panel obtained within 4 weeks prior to registration on study
• Adequate liver function, defined as total bilirubin \<5 mg/dL, serum albumin \>2.0g/dL, serum levels of liver enzymes \< 5 times the upper limit of normal, and INR \< 1.5
• Previous liver resection or ablative therapy is permitted
• Chemotherapy and/or targeted agent therapy must be completed at least 2 weeks prior to radiation and started at least 14 days after completion of SBPT Women of childbearing potential and male participants must practice adequate contraception
• Patient must sign study specific informed consent prior to study entry
• Pretreatment evaluations required for eligibility include:
• * A complete history and general physical examination
• * For women of childbearing potential, a serum or urine pregnancy test must be performed within 72 hours prior to registration
• * INR, total bilirubin, albumin, alkaline phosphatase, ALT, AST within 4 weeks prior to study entry

Exclusion Criteria:

• Prior invasive malignancy other than liver met primary (except non-melanomatous skin cancer) unless disease free for \> 3years
• Prior radiotherapy that would results in overlap of radiation fields
• Prior radiotherapy to the liver
• Severe, active co-morbidity that may impact survival
• CNS metastases
• Tense ascites requiring frequent paracentesis
• Active liver infection
• Pregnancy, nursing women, or women of child bearing potential, and men who are sexually active and not willing/able to use medically acceptable forms of contraception
• Metastases location within 2cm of GI tract
• -